OS Therapies Incorporated (OSTX)
NYSEAMERICAN: OSTX · Real-Time Price · USD
1.570
+0.060 (3.97%)
Mar 6, 2026, 4:00 PM EST - Market closed
OS Therapies Employees
As of December 31, 2024, OS Therapies had 5 total employees, including 4 full-time and 1 part-time employees. The number of employees increased by 1 or 25.00% compared to the previous year.
Employees
5
Change
1
Growth
25.00%
Revenue / Employee
n/a
Profits / Employee
-$4,051,244
Market Cap
55.29M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5 | 1 | 25.00% |
| Dec 31, 2022 | 4 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| MindWalk Holdings | 102 |
| Acrivon Therapeutics | 78 |
| Kezar Life Sciences | 55 |
| LeonaBio | 26 |
| MiNK Therapeutics | 23 |
| Plus Therapeutics | 21 |
| Lipocine | 16 |
| Rallybio | 15 |
OSTX News
- 18 days ago - OS Therapies Discloses 2026 Timeline For Lead Drug Regulatory Filings - Benzinga
- 18 days ago - OS Therapies Provides Global Regulatory Update for OST-HER2 in Recurrent, Fully Resected, Pulmonary Metstatic Osteosarcoma - Newsfile Corp
- 4 weeks ago - OS Therapies Applauds Reauthorization of Pediatric Priority Review Voucher Program to Advance Breakthrough Osteosarcoma Immunotherapies - Newsfile Corp
- 4 weeks ago - OS Therapies Initiates US FDA BLA Filing for OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Newsfile Corp
- 7 weeks ago - OS Therapies Bone Cancer Trial Data Strengthens FDA Case - Benzinga
- 7 weeks ago - OS Therapies Announces Positive Biomarker Data from Phase 2b Clinical Trial of OST-HER2 in the Prevention or Delay of Recurrent, Fully Resected, Pulmonary Metastatic Osteosarcoma - Newsfile Corp
- 7 weeks ago - OS Therapies Announces Filing Form S-1 of OS Animal Health Subsidiary - Newsfile Corp
- 7 weeks ago - OS Therapies Enters into Warrant Inducement Agreements - Newsfile Corp